ConductScience.org, home

Paper17545614

Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.

Sui M and 4 others. Cancer Res, 2007. Cited by 87 papers, by iCite.

Cite this record

ConductScience Library. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Papers, record 17545614. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17545614

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
PubMed
Journal
Cancer Res
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
87
iCite
Relative citation ratio, by iCite
2.09
iCite
Revised in PubMed
2021-12-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sui MMeihua
2Huang YYi
3Park BHBen Ho
4Davidson NENancy E
5Fan WWeimin

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Estrogen Receptor alphaMajor topic
PaclitaxelMajor topic
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Cell Line, Tumor
Drug Resistance, Neoplasm
Drug Synergism
Estradiol
Fulvestrant
Humans
Microtubules
Mitosis
Prohibitins
Transfection

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA109274NCI NIH HHSUnited StatesR01CA109274PubMed and NIHNIH RePORTER
CA88843NCI NIH HHSUnited StatesP50CA088843PubMed and NIHNIH RePORTER
CA92280NCI NIH HHSUnited StatesR01CA092280PubMed and NIHNIH RePORTER
R55CA109274NIHNIH RePORTER

Download CSV of grants

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 87 citations.

PMIDTitleJournalYearIn PapersSource
40958617Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer.Ann Med2025https://conductscience.org/library/papers/40958617PubMed
40176396Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.Thorac Cancer2025https://conductscience.org/library/papers/40176396PubMed
38851818Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer.NPJ Breast Cancer2024https://conductscience.org/library/papers/38851818PubMed
38393465The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast.Mol Biol Rep2024https://conductscience.org/library/papers/38393465PubMed
38187046Estrogen receptor α inhibits Caveolin 1 translation by promoting m6A-dependent miR199a-5p maturation to confer nab-paclitaxel resistance.Am J Cancer Res2023https://conductscience.org/library/papers/38187046PubMed
36241702Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway.Cancer Gene Ther2023https://conductscience.org/library/papers/36241702PubMed
33207722Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer.Brain Sci2020https://conductscience.org/library/papers/33207722PubMed
32975708
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Breast Cancer Res Treat2021https://conductscience.org/library/papers/32975708PubMed
32781533Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects.Int J Mol Sci2020https://conductscience.org/library/papers/32781533PubMed
32765594Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis.Front Genet2020https://conductscience.org/library/papers/32765594PubMed
32158193NVP-BSK805, an Inhibitor of JAK2 Kinase, Significantly Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma in vitro and in vivo.Drug Des Devel Ther2020https://conductscience.org/library/papers/32158193PubMed
309376574-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.Breast Cancer Res Treat2019https://conductscience.org/library/papers/30937657PubMed
30179299Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.J Cell Mol Med2018https://conductscience.org/library/papers/30179299PubMed
29937544Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.Br J Cancer2018https://conductscience.org/library/papers/29937544PubMed
29430288Synthesis and Biological Evaluations of Ring Substituted Tetrahydroisoquinolines (THIQs) as Anti-Breast Cancer Agents.J Cancer Sci Ther2017https://conductscience.org/library/papers/29430288PubMed
29373839Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.Cancer Lett2018https://conductscience.org/library/papers/29373839PubMed
28747642A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel.Sci Rep2017https://conductscience.org/library/papers/28747642PubMed
28081544Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.Br J Cancer2017https://conductscience.org/library/papers/28081544PubMed
28000875Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.Oncol Rep2017https://conductscience.org/library/papers/28000875PubMed
27845892LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.Oncotarget2016https://conductscience.org/library/papers/27845892PubMed

See all 54 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17545614

GET https://conductscience.org/api/papers/v1/17545614/cited_by?page=2